Regeneron Pharmaceuticals (NASDAQ:REGN) Earns Buy Rating from Canaccord Genuity Group

Regeneron Pharmaceuticals (NASDAQ:REGN)‘s stock had its “buy” rating restated by equities research analysts at Canaccord Genuity Group in a report issued on Thursday, Benzinga reports. They currently have a $1,152.00 price objective on the biopharmaceutical company’s stock. Canaccord Genuity Group’s price target would suggest a potential upside of 7.78% from the stock’s current price.

A number of other equities research analysts have also commented on the company. JPMorgan Chase & Co. raised their price target on Regeneron Pharmaceuticals from $1,050.00 to $1,150.00 and gave the stock an “overweight” rating in a research report on Monday, June 17th. Sanford C. Bernstein initiated coverage on Regeneron Pharmaceuticals in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $1,125.00 target price on the stock. Royal Bank of Canada restated an “outperform” rating and issued a $1,229.00 price target on shares of Regeneron Pharmaceuticals in a research note on Monday. Evercore ISI initiated coverage on Regeneron Pharmaceuticals in a report on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective for the company. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $925.00 target price on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $1,015.91.

Regeneron Pharmaceuticals Trading Down 0.0 %

Shares of Regeneron Pharmaceuticals stock traded down $0.33 on Thursday, hitting $1,068.83. 17,098 shares of the company’s stock traded hands, compared to its average volume of 474,043. The firm’s 50-day moving average price is $974.69 and its two-hundred day moving average price is $947.43. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.27 and a quick ratio of 4.51. The stock has a market capitalization of $117.77 billion, a PE ratio of 31.58, a price-to-earnings-growth ratio of 2.21 and a beta of 0.13. Regeneron Pharmaceuticals has a one year low of $684.80 and a one year high of $1,081.17.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings data on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing analysts’ consensus estimates of $8.46 by ($0.49). Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. The company had revenue of $3.15 billion during the quarter, compared to the consensus estimate of $3.19 billion. On average, research analysts expect that Regeneron Pharmaceuticals will post 37.23 EPS for the current fiscal year.

Insider Buying and Selling

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction that occurred on Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the transaction, the chief executive officer now directly owns 408,200 shares in the company, valued at approximately $399,729,850. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other news, CEO Leonard S. Schleifer sold 25,000 shares of the business’s stock in a transaction on Tuesday, May 14th. The stock was sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the transaction, the chief executive officer now owns 408,200 shares of the company’s stock, valued at approximately $399,729,850. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bonnie L. Bassler sold 756 shares of the business’s stock in a transaction dated Monday, June 24th. The stock was sold at an average price of $1,062.00, for a total value of $802,872.00. Following the transaction, the director now directly owns 1,382 shares of the company’s stock, valued at approximately $1,467,684. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 61,971 shares of company stock worth $61,217,654. Company insiders own 7.48% of the company’s stock.

Institutional Investors Weigh In On Regeneron Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. Sierra Summit Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth about $1,011,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at about $749,000. Public Employees Retirement Association of Colorado increased its stake in shares of Regeneron Pharmaceuticals by 16.0% in the fourth quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock valued at $14,118,000 after buying an additional 2,220 shares during the period. Exchange Traded Concepts LLC boosted its holdings in Regeneron Pharmaceuticals by 32.7% in the fourth quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after acquiring an additional 1,221 shares during the last quarter. Finally, Congress Wealth Management LLC DE bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $271,000. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.